Development of a Multiplex PCR Assay for Rapid Molecular Serotyping of Haemophilus parasuis by Howell, K J et al.
Development of a Multiplex PCR Assay for Rapid Molecular
Serotyping of Haemophilus parasuis
Kate J. Howell,a Sarah E. Peters,a Jinhong Wang,a Juan Hernandez-Garcia,a Lucy A. Weinert,a Shi-Lu Luan,a Roy R. Chaudhuri,b
Øystein Angen,c Virginia Aragon,d Susanna M. Williamson,e Julian Parkhill,f Paul R. Langford,g Andrew N. Rycroft,h
Brendan W. Wren,i Duncan J. Maskell,a Alexander W. Tucker,a on behalf of the BRaDP1T Consortium
Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdoma; Department of Molecular Biology and Biotechnology, University of Sheffield,
Western Bank, Sheffield, United Kingdomb; Norwegian Veterinary Institute, Oslo, Norwayc; Centre de Recerca en Sanitat Animal (CReSA), UAB-IRTA, Campus de la
Universitat Autònoma de Barcelona, Bellaterra, and Institut de Recerca i Tecnologia Agroalimentàries (IRTA), Barcelona, Spaind; Animal and Plant Health Agency (APHA),
Suffolk, United Kingdome; The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdomf; Section of Paediatrics,
Department of Medicine, Imperial College London, St. Mary’s Campus, London, United Kingdomg; The Royal Veterinary College, Hawkshead Campus, Hatfield,
Hertfordshire, United Kingdomh; Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdomi
Haemophilus parasuis causes Glässer’s disease and pneumonia in pigs. Indirect hemagglutination (IHA) is typically used to se-
rotype this bacterium, distinguishing 15 serovars with some nontypeable isolates. The capsule loci of the 15 reference strains
have been annotated, and significant genetic variation was identified between serovars, with the exception of serovars 5 and 12. A
capsule locus and in silico serovar were identified for all but two nontypeable isolates in our collection of>200 isolates. Here, we
describe the development of a multiplex PCR, based on variation within the capsule loci of the 15 serovars of H. parasuis, for
rapid molecular serotyping. The multiplex PCR (mPCR) distinguished between all previously described serovars except 5 and
12, which were detected by the same pair of primers. The detection limit of the mPCR was 4.29 105 ng/l bacterial genomic
DNA, and high specificity was indicated by the absence of reactivity against closely related commensal Pasteurellaceae and other
bacterial pathogens of pigs. A subset of 150 isolates from a previously sequenced H. parasuis collection was used to validate the
mPCR with 100% accuracy compared to the in silico results. In addition, the two in silico-nontypeable isolates were typeable
using the mPCR. A further 84 isolates were analyzed by mPCR and compared to the IHA serotyping results with 90% concor-
dance (excluding those that were nontypeable by IHA). The mPCR was faster, more sensitive, and more specific than IHA, en-
abling the differentiation of 14 of the 15 serovars of H. parasuis.
Haemophilus parasuis is aGram-negative bacteriumcommonlyfound in the upper respiratory tract of the pig, and it was
identified in 1910 as the causative agent of a globally prevalent
systemic disease of pigs known as Glässer’s disease. The more se-
vere presentations of this disease include arthritis,meningitis, pol-
yserositis, septicemia, and pneumonia (1–5). Based on statistics
from the United States,H. parasuis is the leading cause of mortal-
ity (alongside the porcine reproductive and respiratory syndrome
[PRRS] virus) in nursery herds, and it is the third most important
bacterial pathogen affecting finisher herds (6). H. parasuis also
contributes to a multifactorial porcine respiratory disease com-
plex, the leading cause of mortality in grower-finisher pigs in the
United States (7). Diagnostic submissions to veterinary investiga-
tion centers of the Animal and Plant Health Agency (APHA) in
2013 and 2014 recorded the highest annual rates of diagnosis of
disease incidents due to H. parasuis in England and Wales since
2002 (8, 9). In the third quarter of 2013, the diagnostic rate
reached nearly 8% of diagnosable submissions (8, 9). This disease
characteristicallymanifests postweaning and is associatedwith the
loss of maternally derived antibodies and the endemic presence of
the bacterium in herds (1, 5).
Treatment and prevention of Glässer’s disease are imple-
mented via strategic delivery of penicillin-based antimicrobials in
feed or water. Ongoing treatment may be administered to succes-
sive batches of susceptible pigs for several months after an out-
break to ensure the full recovery of the herd (5, 10, 11). Regular
medication of farmed livestock is of concern, as antimicrobial
resistance may be selected by the prolonged use of these drugs.
Antimicrobial resistance inH. parasuishas been reported inChina
and Spain, where themajority ofH. parasuis strains are resistant to
enrofloxacin and trimethoprim (10, 12, 13). Control of stock
movement in and out of the herd is currently the best method
of prevention, as it reduces the risk of introducing new strains
(5, 14, 15).
The current commercially available vaccines are bacterins,
which are protective only against strains of the same serovar (16–
18), and which primarily target the disease-causing serovars 4 and
5, with limited cross-protection against others (5, 19, 20). It is
possible to make autogenous vaccines in response to an outbreak
of Glässer’s disease, which can be useful if the serovar is different
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from that targeted by the commercial vaccines (21), but this is an
expensive and time-consuming option. In addition, multiple iso-
lates, often of different serovars, may be present within an indi-
vidual or a herd, which can result in the wrong isolate being cho-
sen for the production of the autogenous vaccine.
Serotyping is the most frequently used subtyping method for
H. parasuis, as it is important for guiding the vaccination strategy
to try to prevent future outbreaks. The current serotyping scheme,
based on reactions between antisera and surface antigens, classi-
fies the bacteria into 15 serovars, with a considerable number of
nontypeable (NT) isolates observed (22, 23).Most commonly iso-
lated from the field are serovars 4, 5, and 13 (24–27). However,
isolates are collected predominantly from severely affected indi-
viduals or clinical cases from within a herd, with only a single
colony studied from those cultured from a swab. As multiple in-
fections of the same individual and within herds can occur (25,
27–29), there may be additional isolates that contribute to disease
in animals that are not commonly investigated. The site of isola-
tion is also very important, as isolates cultured from the joints or
frommeninges have survived serum killing and phagocytosis and
so are highly likely to be virulent; however, if samples are taken
from the upper respiratory tract or the lung, there is a higher
chance of the isolate being part of a coinfection rather than the
isolate responsible for the disease. This might well introduce sam-
pling bias, and the relative proportions of different serovars
among isolates actively causing disease and carriage isolates in pig
populations may vary from the commonly reported serovars 4, 5,
and 13 (24–27).
The Kielstein-Rapp-Gabrielson serotyping scheme was the
first to identify the 15 serovars ofH. parasuis in 1992 using the gel
immunodiffusion assay (GID) (23), which has since been super-
seded by an indirect hemagglutination assay (IHA) (30–32); this
has increased the proportion of typeable strains from60% to 80%.
An isolatemay be reported as nontypeable if there is no observable
reaction, or when four or more different antisera react with the
same isolate. A serotyping result can include cross-reactions when
two or three antisera react with an isolate, and this is common for
field isolates using both serotyping methods (23, 25, 30, 33). In
these circumstances, the strongest agglutination reaction is cho-
sen as the main serotyping result, but this can be dependent on
visual interpretation by the worker, so human error is introduced
into the test. Therefore, even with 80% of isolates being typeable,
this success rate is susceptible to errors that reduce accuracy. Im-
provements in the accuracy of H. parasuis serotyping would aid
the understanding of the epidemiology of this pathogen and allow
optimization of vaccination strategies for the prevention of dis-
ease.
There are other drawbacks of the IHA serotyping assay, includ-
ing the difficulty of consistently producing specific antisera
against several reference strains (30), variation in growth condi-
tions or growth rates between isolates, the very small number of
laboratories that currently perform this test, and the repeatability
or robustness of methods and results between these laboratories
(23, 31, 34, 35). The method is also time-consuming, expensive,
and requires pure culture of an isolate.
Molecular typing should be considered a potentially more ac-
curate and consistent test. These techniques have been developed
for other bacteria based on the genes involved in biosynthesis of
extracellular polysaccharide structures, such as lipopolysaccha-
rides (LPS) or capsules (36–39). These are also likely to be the
dominant components of the serotyping antigens for H. parasuis
based on the antigen preparation techniques for both theGID and
IHAmethods (22, 23, 30, 31). Genes encoding these surface com-
ponents were therefore the elements of the genome investigated
for molecular serotyping markers. An analysis of the first com-
plete H. parasuis genome sequence (strain SH0165) identified a
14-kb polysaccharide biosynthesis region that was proposed to
encodeO antigen, with 12 coding sequences in the same transcrip-
tional direction. It was later proposed that this is in fact a group 1
capsule locus based on the presence of the homologues of thewza,
wzb, and wzc genes, and it is responsible for considerable serovar-
specific variation (40–43). Furthermore, there is a strong associa-
tion between the presence of particular capsule loci and serotyping
results (44), with 85% of the reference strains studied having the
same serotyping result from in silico analysis and IHA. Those iso-
lates with different resultsmatched to one of the cross-reactions in
the IHA result. In addition, isolates that had been nontypeable
(NT) by IHA contained a capsule locus thatmatched one of the 15
reference strains, with two exceptions (43, 44). These two isolates
had capsule genes similar to those identified in serovars 6 and 8,
but they had not been assembled onto a single contiguous se-
quence (contig) or capsule locus and so further investigation.
Here, we describe the design of a molecular serotyping PCR,
based on variations within the capsule loci, capable of discrimi-
nating between 14 of the 15 serovars ofH. parasuis. In addition, a
new species-specific molecular marker forH. parasuis was identi-
fied and included in the multiplex PCR (mPCR).
MATERIALS AND METHODS
Isolate collections. For the design of this molecular serotyping test, we
used a previously described (44) collection of 212 isolates of H. parasuis,
117 of which had been serotyped by IHA. This collection included isolates
cultured from pig tissues during diagnostic investigations at the Animal
and Plant Health Agency (APHA) from farms in England and Wales be-
tween 1993 and 2011, isolates from Denmark, Spain, and Australia, and
the 15 serotyping reference strains. This collection included disease- and
nondisease-associated isolates, all of which had their genomes sequenced
by genomic DNA (gDNA) extraction and paired-end Illumina sequenc-
ing, as described previously (44). The genome sequences of these isolates
were examined for the presence of a capsule locus, and for all but two of
them, a serovar was predicted in silico based on the capsule genes (44). A
subset of 150 isolates from this original collection was used for the valida-
tion of the mPCR, 117 of which had been serotyped by IHA and for all of
which a serovar had been predicted by in silico analysis. This subset in-
cluded isolates representing all 15 serovars and those previously sero-
typed, including those with cross-reactions (n  22), all nontypeable
isolates (n  19), and a selection of isolates that had not been sero-
typed (n  33).
An additional 84 disease-associated isolates of H. parasuis were col-
lected by the APHA during 2013 and 2014; we called this the additional
isolate collection. Sixty-six of these isolates were serotyped by Innovative
Veterinary Diagnostics (IVD), Germany, using IHA, and were of a variety
of serovars (serovars 1, 2, 4, 5, 6, 9, 13, 14, and 15), in addition to non-
typeable isolates (n  15). Nine of the isolates had cross-reactions re-
ported in their serotyping results. The remaining 18 isolates had not been
tested by IHA and so were of unknown serovar. This additional isolate
collection with unknown capsule loci did not contribute to the original
design of serovar-specific markers and therefore enabled an objective
evaluation of the new mPCR.
Isolates of closely related Pasteurellaceae, including Actinobacillus in-
dolicus, Actinobacillus minor, Actinobacillus porcinus, and Actinobacillus
porcitonsillarum, were identified from routine diagnostic investigations at
the APHA and also had their genomes sequenced (European Nucleotide
Haemophilus parasuis Molecular Serotyping Assay
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Archive accession no. ERS132116, ERS132148, ERS132149, ERS132152 to
ERS132156, ERS132158 to ERS132160, ERS132162 to ERS132165,
ERS132169, and ERS132170). These genomes were evaluated using
BLASTn against the primers designed for H. parasuis, as they are from
species that are most likely to cross-react. These isolates together with
further field isolates of Actinobacillus pleuropneumoniae (n  3), Borde-
tella bronchiseptica (n  1), and Streptococcus suis (n  3), all common
bacteria in the upper respiratory tracts of pigs, were used in this study as
part of a negative-control panel for the mPCR.
Species-specific marker design. A Perl script was used to produce a
draft core genome ofH. parasuis using the genome sequences of the orig-
inal collection (n  212) (44). The protein-coding sequences from the
published complete genome of H. parasuis SH0165 (45) were compared
to theH. parasuis genomes using tBLASTn. If a coding sequence had 80%
identity over 80% of the length of the gene to a contig in all of the H.
parasuis genomes, the gene was considered to be part of the core genome.
This list represents the most conserved genes in the H. parasuis genome.
The SH0165 Fasta sequence for each gene from the core genome was
compared to the nonredundant (nr) NCBI database using BLASTn to
identify geneswithmatches toH. parasuis only. These core geneswere also
compared by BLASTn with the genome sequences of the other Pasteurel-
laceae isolates. Genes withmatches inH. parasuis only were taken forward
as potential species-specific markers. The alignments of the genes were
assessed using alistat (46) to study the average alignment identity and
minimum alignment identity between two sequences in the alignment.
Genes with 95% average alignment identity were chosen to create a
short list of potential species-specific markers with a variety of amplicon
sizes.
Serotyping mPCR design. The capsule loci of the 15 serovar reference
strains were previously sequenced and annotated (43). The majority of
isolates of the same serovar shared high levels of identity in their capsule
loci, as expected (95% for themajority of serovars) (44).Where loci did
not match within the same serovar, the majority of the capsule loci
matched to a recorded cross-reaction (44). Twenty-two isolates in the
original isolate collection had recorded cross-reactions, and four of these
isolates matched to the minor reaction rather than the dominant serovar
in the cross-reaction results. A further 10 isolates in the original isolate
collection had results that were different from the IHA serotyping result.
The agreement between the IHA serotyping and the capsule lociwas tested
using an unweighted Cohen’s kappa test, excluding the NT isolates (47).
Differences in the gene composition were found between the capsule loci
of the reference strains, i.e., between different serovars, with the exception
of serovars 5 and 12, which have 97% identity across the capsule locus
(37); a short list of genes found in only one or two of the 14 known capsule
loci was made, from which primers were designed to distinguish between
the serovars. The original capsule variation diagram from Howell et al.
(43) has been adapted to show the gene differences and target genes for the
multiplex design (see Fig. S1 in the supplemental material).
Primer design. Primer design for the species-specific marker and se-
rotyping markers was as follows. Primer3 (http://www.bioinformatics.nl
/cgi-bin/primer3plus/primer3plus.cgi/) was used to design primers be-
tween 21 and 30 bases in length, with 40 to 60% GC content, based on
recommendations for multiplex PCR (mPCR) design. The primers for
each gene were compared, using BLASTn with a word size of 7, to the nr
database and the closely relatedPasteurellaceae bacterial genomes to check
for any nonspecific primer matches that would rule out any primer se-
quences. The primers were also compared to the H. parasuis genomes
using BLASTn to look for those that matched all of the expected isolates
with only onematch and 100% identity. All those that passed these checks
were then aligned against the target gene, and product sizes were esti-
mated based on all combinations of primers. For several genes, the prim-
ers had to be redesigned manually when no suitable primer met the re-
quirement for the range of product sizes. Primer-dimer and hairpin
structures were predicted for all of the primer combinations using Na-
tional Institute of Standards and Technology Primer Tools (http://yellow
.nist.gov:8444/dnaAnalysis/primerToolsPage.do), and any problematic
primerswere removed from the short list. A pair of primerswas chosen for
each gene, which would give approximately 20 to 50 bp separation be-
tween all amplicons when combined into an mPCR. Primers were ob-
tained in dehydrated desalted form from Sigma-Aldrich (Haverhill, Cam-
bridge, United Kingdom). The final target genes and primers for the
mPCR are shown in Table 1.
Primer optimization. All primers were initially tested using gradient
PCRs using OneTaq Quick-Load 2 master mix with standard buffer
(New England BioLabs), according to the product specifications and pro-
tocols. Amplification of the targets was initiated at 94°C for 30 s, followed
by 30 cycles of 3-step cycling comprising denaturation at 94°C for 30 s and
annealing at a temperature range for the gradient PCR between 52 and
64°C for 30 s, 68°C for 60 s for extension, and a final extension of 68°C for
5 min. Each PCR mixture contained 12.5 l of OneTaq Quick-Load 2
mastermix, 0.25l of each primer (at 20Meach), 2l of gDNA for each
isolate (at10 ng/l), and 10l of UltraPure H2O (Life Technologies) to
a final volume of 25 l. For the individual serovar-specific primers, the
reference strain of each serovar was used as a positive control, and an
isolate from a different serovar was selected as a negative control. Ultra-
Pure H2O was used as a negative control for all PCRs. Gel electrophoresis
was performed in a 2.0% agarose gel in 1Tris-borate-EDTA (TBE) with
5% SYBR Safe dye (Invitrogen) at 120 V for 50min using the Quick-Load
TABLE 1 Serotyping multiplex primers and estimated product sizes





funB CTGTGTATAATCTATCCCCGATCATCAGC GTCCAACAGAATTTGGACCAATTCCTG 1 180
wzx CTAACAAGTTAGGTATGGAGGGTTTTGGTG GGCACTGAATAAGGGATAATTGTACTG 2 295
glyC CATGGTGTTTATCCTGACTTGGCTGT TCCACATGAGGCCGCTTCTAATATACT 3 650
wciP GGTTAAGAGGTAGAGCTAAGAATAGAGG CTTTCCACAACAGCTCTAGAAACC 4 320
wcwK CCACTGGATAGAGAGTGGCAGG CCATACATCTGAATTCCTAAGC 5 or 12 450
gltI GATTCTGATGATTTTTGGCTGACGGAACG CCTATTCTGTCTATAAGCATAGACAGGAC 6 360
funQ CTCCGATTTCATCTTTTCTATGTGG CGATAAACCATAACAATTCCTGGCAC 7 490
scdA GGAAGGGGATTACTACTACCTGAAAG CTCCATAGAACCTGCTGCTTGAG 8 650
funV AGCCACATCAATTTTAGCCTCATCA CCTTAAATAGCCTATGTCTGTACC 9 710
funX GGTGACATTTATGGGCGAGTAAGTC GCACTGTCATCAATAACAATCTTAAGACG 10 790
amtA CCATCTCTTTAACTAATGGGACTG GGACGCCAAGGAGTATTATCAAATG 11 890
gltP GCTGGAGGAGTTGAAAGAGTTGTTAC CAATCAAATGAAACAACAGGAAGC 13 840
funAB GCTGGTTATGACTATTTCTTTCGCG GCTCCCAAGATTAAACCACAAGCAAG 14 730
funI CAAGTTCGGATTGGGAGCATATATC CCTATATCATTTGTTGGATGTACG 15 550
HPS_219690793 ACAACCTGCAAGTACTTATCGGGAT TAGCCTCCTGTCTGATATTCCCACG All 275
Howell et al.
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100-bp DNA ladder (New England BioLabs) as the molecular size stan-
dard. All results were analyzed using aGelDocXR imager (Bio-Rad). Each
pair of primers was then tested on the panel of reference strains for the 15
serovars (see Table S1 in the supplemental material) using 25-l PCRs
and the PCR protocol described above, with a consensus annealing tem-
perature of 64°C from the individual gradient PCRs. PCRpurificationwas
performed using a 50-l PCR and the QIAquick PCR purification kit
(Qiagen), as per the manufacturer’s instructions. PCR products were se-
quenced using the Source BioScience Sanger sequencing service. The se-
quences of the products were aligned with the target gene and primers
using SeaView (48).
One-step mPCR. The successful primers for the mPCR were com-
bined to create a 50 M primer mix using 1 Tris-EDTA (TE) buffer.
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) was added to the PCRs at
1% of the total reaction volume, and the annealing temperature was re-
duced to 58°C to improve the production of bands of equal intensity. The
primer mixes were also optimized, aiming for equal intensity for each
amplicon, with a ratio of 1:0.25 serovar-specific primers to species-spe-
cific primers. The final PCRmix included 12.5l of OneTaqQuick-Load
2master mix, 3 l of the primer mix, 2 l of gDNA for each isolate (at
10 ng/l), and 7.25 l of UltraPure H2O to a final volume of 25 l. Gel
electrophoresis for the mPCR was extended to 90 min for better separa-
tion of the amplicons.
ThemPCRwas tested on 234 isolates (a subset of 150 isolates from the
original isolate collection and the additional isolate collection of 84 iso-
lates) and was repeated in triplicate using separate master mixes to dem-
onstrate the repeatability and accuracy of the mPCR. For the subset of the
original isolate collection, themPCR results were compared to the in silico
serovar predictions. For the additional isolate collection, it was only pos-
sible to compare the mPCR result to the IHA serotyping result if known.
Genomic DNA extraction requires pure culture, can be time-consum-
ing, and adds additional cost to the diagnosis procedure; therefore, colony
PCRmethods can be more convenient for diagnostic laboratories. There-
fore, for comparison, 20 isolates from the additional isolate collection
were also tested using a colony PCRmethod. A loopful of bacteria from a
passaged plate of pure culturewas resuspended in 50l ofUltraPureH2O,
which was heated to 100°C for 30 min and centrifuged at 4,000 g for 1
min, and the supernatant was used in the mPCR reaction. The same vol-
ume of supernatant was used in themPCR reactionmixture as the volume
that was used for pure genomic DNA. The results of mPCR were com-
pared to those of the IHA serotyping method (where available).
Limit of detection of the mPCR. The concentration of gDNA was
measured for five reference strains (strain name-serovar: HS145-S1,
SW140-S2, Nagasaki-S5, C5-S8, D74-Aus–S9, and IA84/17975-S13) us-
ing a Qubit fluorometer (Life Technologies) with broad-range standards.
Six serial dilutions of this DNA in UltraPure H2O were used as the tem-
plate in the mPCR to estimate its limit of detection. This was then
calculated in genomes per microliter based on the average genome size of
2.26 Mb.
RESULTS
Design of the serotyping mPCR. Based on the in silico analyses of
the capsule loci (44), a serovar was predicted for all except two of
theH. parasuis isolates in the original collection (n 212), includ-
ing those that were previously determined to be NT using the IHA
method (44). Cohen’s kappa (47) was used to test the agreement
between the IHA and in silico analyses (for isolates for which both
resultswereavailable) andwas statistically significant (P0.01),with
the individual serovars treated as categories. The two exceptions had
incomplete capsule locus sequences, but the genes identified were
highly similar to those from capsule loci from serovars 6 and 8.
Fourteen isolates were discrepant between the in silico serovar
prediction and the IHA results, with four isolates matching to the
cross-reaction: a serovar 12 with cross-reactions to serovars 2 and
4 result was identified as a serovar 2 isolate, and serovar 7 isolates
with cross-reactions identified as serovar 4. The remaining isolates
were a serovar 2 identified as a serovar 1, a serovar 7 identified as a
serovar 9, a serovar 7 with serovar 2 cross-reaction identified as a
serovar 4, three serovar 7 isolates identified as serovar 4, a serovar
11 identified as a serovar 13, a serovar 13 identified as a serovar 5
or 12, and two serovar 14 isolates identified as a serovar 13.
Given the success of predicting serovar by in silico analysis, we
assessed the serovar prevalence of the 117 isolates, which had been
serotyped by IHA and were compared with the in silico prediction
of the serovar of those isolates in the original collection (Fig. 1)
FIG 1 Serovar prevalence of 117 isolates that had been serotyped by IHA (blue) in comparison with the in silico serovar predicted for the same isolates based on
analysis of the capsule loci (red). The agreement between the IHA and in silico serovar prediction was tested using an unweighted Cohen’s kappa test, with a P
value of 0.0000128, excluding the NT isolates.
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(44). From the original IHA serotyping results, serovars 5, NT, 4,
7, and 13 were themost prevalent serovars, in order of descending
frequency. In comparison, the in silico results for all isolates
showed that serovar 5 was the most prevalent, closely followed by
serovar 4 and then by serovars 13 and 7, and none of the isolates
were NT by the in silico analysis, in comparison to 19 out of 117
that were NT by IHA serotyping.
The large amount of genetic variation between the capsule loci
of the 15 serovars was chosen as the target for a molecular sero-
typing assay. The assay was designed using a wide variety of genes
from within the capsule loci, including an aminotransferase, gly-
cosyltransferases, O-antigen flippase, and genes with unknown
function; overall, these genes share51% identity at the nucleo-
tide level. The target genes among the variable region can be seen
in Fig. S1 in the supplemental material. It was not possible to
detect differences between serovars 5 and 12 based on the DNA
sequences of the capsule loci from any of the examples in the
original isolate collection. Even upon detailed analysis of the
whole genomes of the serovar 5 and 12 isolates, it was not possible
to identify sequence markers to distinguish between these sero-
vars, indicating that theremust be a subtle difference in expression
of a gene or genes, or that the difference between serovars 5 and 12
is an artifact of the IHA typing antibodies. This finding is consis-
tent with the high frequency of cross-reactions between these se-
rovars according to the IHA test (30). At least one target gene per
serovar was identified (counting serovars 5 and 12 as the same
serovar), except for serovar 1, for which the same gene was also
identified in serovars 2 and 11. A gene of unknown function
(funB) was chosen as the marker for serovar 1, which was also
identified in serovar 11 and was highly similar to another gene of
unknown function in serovar 2 (funE). The distinguishing prim-
FIG 2 Band patterns for the molecular serotyping PCR for all 15 serovars of H. parasuis. Lane M, Quick-Load 100-bp DNA ladder (NEB); S1 to S15 represent
the 15 serovars of H. parasuis. Sp-sp, species-specific marker.
FIG 3 Negative-control panel showing specificity of the primer sets across a
range commensal and pathogenic bacteria found in the pig respiratory tract
(H. parasuis-positive controls serovar 2 and 5, A. minor, A. porcinus, A. in-
dolicus, S. suis, A. pleuropneumoniae, and B. bronchiseptica). Lane M, Quick-
Load 100-bp marker (NEB) and H2O as the negative control.
Howell et al.
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ers for serovar 2 were designed against a divergent wzx gene, and
the amtA gene was used to identify serovar 11 (Fig. 2). By individ-
ually testing the serovar-specific primer pairs, it was shown that
each pair gave an amplicon of the expected size, each of which was
produced only by the expected serovar (Fig. 2) and each of which
had the correctDNA sequence. The banding patterns produced by
the reference strains in the serovar-specific PCRs, and the new H.
parasuis species-specific marker, with an amplicon size of 275 bp,
is shown in Fig. 2. This species-specific marker (HPS_219690793,
with unknown function) was chosen from a short list of highly
conserved genes from the core genome, as it fit best with the sero-
var-specific amplicon sizes.
During the optimization of the mPCR, PCR product purifica-
tion was performed for each pair of primers using two or three
isolates of each serovar, and alignments of the sequenced PCR
products with the target gene showed that they were the correct
products. The specificities of the serotyping mPCR primers were
tested against six other species commonly found in the upper re-
spiratory tract of the pig, including closely related Pasteurellaceae
and other pig pathogens. No products were amplified from these
other species, strongly indicating that these primers are specific for
H. parasuis (Fig. 3). Using DNA isolated from six reference strains
of H. parasuis, the average minimum concentration of DNA de-
tectable by the mPCR was determined to be 1 ng/l for an indi-
vidual pure gDNA preparation or 4.29  105 genomes/l across
the serovars (Fig. 4).
Validation of the serotyping multiplex. The molecular sero-
typing assay was validated using 150 isolates covering all 15 sero-
vars, including 117 isolates thatwere previously serotyped by IHA,
19 of which were deemed nontypeable. A summary of the results
of this validation exercise and a comparison with the original IHA
results and in silico serovars are shown in Table 2. The mPCR
produced the predicted amplicons at the expected sizes based on
the predicted serovar from the in silico analyses (44) and therefore
was 100% accurate. A serovar was assigned to every isolate by the
mPCR, and no cross-reactions were observed. The two isolates
with incomplete capsule loci were typed as serovars 6 and 8 by the
mPCR. For 33 isolates, the serovar identified by IHAwas different
from that assigned by the in silico or mPCR method. These in-
cluded the 19 isolates that were NT by IHA, which were identified
as serovars 4, 5, 6, 7, 8, 9, 13, and 14 by the mPCR (Table 2), and
the remaining isolatesmatched to theminor cross-reactions or the
previously mentioned discrepancies between the capsule types
and the IHA results.
A summary of the results of the mPCR for the additional col-
lection of 84 isolates, collected during 2013 and 2014, is shown in
FIG 4 Determination of the limit of detection for the serotyping multiplex based on pure genomic DNA for the reference strains of serovars 1, 2, 5, 8, 9, and 13.
The unit of genomes per microliter is used. Lane M, Quick-Load 100-bp marker (NEB) and H2O as the negative control.
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Table 3. Of the 66 isolates previously tested by IHA, a serovar was
determined only in 51, and 15 were classed as NT, all of which
were assigned a serovar by the mPCR. There were also six isolates
in this collection that were assigned different serovars when tested
bymPCR versus IHA.Overall, the IHA serotyping and the in silico
serovar predictions were 90% concordant. From these results, it is
clear that serovar 4was themost prevalent disease-causing serovar
in the United Kingdom in the period of 2013 to 2014, with serovar
5 being the next most prevalent. All results from the colony PCR
were identical to the results using gDNA (data not shown).
DISCUSSION
We have developed a multiplex PCR for rapid molecular serotyp-
ing of H. parasuis based on genetic variation within its capsule
locus. This mPCR discriminated between all serovars of H. para-
suis except serovars 5 and 12, inwhich the capsule loci are identical
(43). The high similarity in gene content of the capsule loci of
serovars 1, 2, and 11, which is likely to be due to diversification
from a single precursor capsule locus (43),made the identification
of a single specific marker for these serovars more difficult; how-
ever, we have shown that they can be reliably distinguished using
the primer pairs described here.
So far, despite our extensive efforts, no gene to differentiate
between serovars 5 and 12 has been identified from the available
whole-genome sequences of these serovars. In the future, itmay be
possible to identify a definitive genetic determinant that is respon-
sible for the separation of these two serovars, but it is also possible
that these are in fact not separate serovars. To determine if sero-
vars 5 and 12 really are distinct, it may be necessary to study more
closely their capsule structures or the composition of the antigens
used in the IHA serotyping assay. This might point, for example,
to a difference in gene expression rather than the presence or
TABLE 2 Summary of the mPCR serotyping results from 150 isolates, showing that the majority of isolates tested had the same result by IHA





isolates1 2 3 4 5 or 12 6 7 8 9 10 11 13 14 15 NT Unknown
1 3 1 2 6
2 6 1 4 11
3 2 0 2
4 13 7 4 5 29
5 or 12 25 1 1 5 32
6 4 2 4 10
7 4 7 4 15
8 2 1 2 5
9 1 4 1 1 7
10 2 0 2
11 2 0 2
13 1 9 2 2 3 17
14 6 1 1 8
15 2 2 4
NT 0 0
a All nontypeable (NT) isolates were assigned a serovar by the mPCR (n 19). An additional subset of 40 isolates was tested with the mPCR that had not been tested by IHA
serotyping (unknown), all of which were assigned a serovar using the mPCR.





isolates1 2 3 4 5 or 12 6 7 8 9 10 11 13 14 15 NT Unknown
1 4 4
2 3 2 5
3 0
4 17 2 6 25
5 or 12 11 4 4 19
6 1 1 2





13 2 2 1 1 1 7
14 1 4 5
15 2 5 7
a Cross-reactions in the IHA result were ignored for this comparison. All nontypeable (NT) isolates were assigned a serovar by the mPCR. The unknown isolates had not been
serotyped by IHA at the time of testing with the mPCR, but all were assigned a serovar using this mPCR.
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absence of an allele, as the determinant of the difference between
serovars 5 and 12 increased by typing antisera. In theUnitedKing-
dom, the Porcilis Glässer vaccine cross-protects (18) between se-
rovars 5 and 12, and so no immediate negative consequences can
be seen from the grouping of serovars 5 and 12 in thismPCRassay.
Conventionally, IHA serotyping is considered the gold stan-
dard with which to compare our mPCR results. However, IHA
serotyping has several well-known drawbacks (nontypeable iso-
lates, cross-reactions, and difficulties in producing antisera) that
make it somewhat unreliable and difficult to perform. We previ-
ously identified a high level of association between the capsule loci
or capsule type of an isolate and the IHA serotyping results (44).
Based on these results, we have proposed that the capsule locus is
likely to encode the dominant component of the serotyping anti-
gens (43, 44). All nontypeable isolates tested with the mPCR were
assigned to a capsule type, with only 12% of isolates assigned to a
different serovar than that predicted by IHA excluding NT iso-
lates. The majority of the isolates with cross-reactions matched to
the strongest cross-reaction, but four isolates matched to the mi-
nor cross-reaction in the serotyping result. The accuracy of the
mPCR can be considered in two ways. First, if we compare the
mPCR results to the IHA results, taking the IHA results as the gold
standard, the mPCRwas 87% accurate for isolates of known sero-
var for the original collection and 78% accurate for the additional
isolate collection. However, the mPCR was able to type 100% of
the tested isolates compared to IHA, which identified only 83% of
the original collection and 77% of the additional collection.
Therefore, it is perhaps more appropriate to consider that the in
silico serovar is the new gold standard, in which case we estimate
that the IHA serotypingmethod is only 72% accurate based on the
concordance between the two methods and the total number of
isolates tested. This takes into account the NT isolates and those
with results that differ between the two methods. It is of course
possible that IHA truly reflects the effective serovar of the bacte-
riumwhen it is being tested in the laboratory, in that capsule gene
expression might be off under these conditions, but we contend
that the mPCR is more useful in these circumstances if the sero-
typing is being performed to obtainmaximum information about
the isolate and to help define disease potential.
Surveillance of this bacterium is focused on the isolates that are
responsible for clinical disease cases, and only a single purified
colony isolated froma case is usually serotyped, due to the expense
of the current IHA test. This means that potential multiple infec-
tions (4, 29, 49) are not routinelymonitored in pig herds (whether
they are disease-associated or carriage isolates); therefore, the real
prevalence of serovars may differ from that reported in the litera-
ture. In contrast, this mPCR can use a loopful of bacteria, whether
from passaging a colony or using multiple colonies grown from a
clinical sample that might contain colonies of different serovars;
thus, wemight be able to detect multiple serovars ofH. parasuis at
once from a single clinical sample. This mPCR would also allow
the testing of multiple purified single colonies of H. parasuis that
may be grown from a single clinical sample. These surveillance
strategies would give more comprehensive figures for carriage
rates and coinfection rates for the different serovars within indi-
viduals or at the herd level. The availability of molecular methods
for detecting this fastidious organism in postmortem tissues
would allow formorewidespread application of the test andmight
enable a more accurate understanding of the true contribution of
different serovars to clinical disease. For example, serovar-based
differences in ease of culture and isolation may exist that can be
overcome by new molecular detection methods. In the future, it
may be also possible to detectH. parasuis in more accessible sam-
ple sites, such as the nasal cavity or oral fluid. This would pave the
way for prospective sampling of herds. The removal of or reduc-
tion in cross-reactions will also make a clearer picture for the
decision to vaccinate, particularly between serovars 4 and 7, which
is a common cross-reaction in the United Kingdom. Rapid sero-
var identification will enable earlier introduction of prophylactic
vaccination.However, the presence ofmultiple isolates ofH. para-
suis in the same animal (4, 29, 49) may mean that care needs to be
taken when interpreting the results. There have been reports that
some serovars aremore virulent than others, for example, serovars
5 and 13 (1, 23, 50), and mPCR results will help determine
whether or not multiple virulent serovars or a mixture of virulent
and avirulent serovars is present in a sample.
In summary, we have developed amolecular serotypingmPCR
that can differentiate 14 of the 15 serovars ofH. parasuis. A total of
234 H. parasuis isolates from two isolate collections were tested
using this new assay, and 100% of the isolates were serotypeable
using the mPCR. There were no ambiguous cross-reactions be-
tween different serovars of H. parasuis, nor were there any cross-
reactions with any other commensal or pathogenic bacteria tested
to date. Of the isolates tested by mPCR, 12% had results that
differed from the IHA serotyping assays (NT isolates excluded),
and much of this variance is explained by previously discussed
difficulties with the IHA method. Therefore, this molecular sero-
typing assay is a significant improvement on the currentmethods,
reducing nontypeability, ambiguity, and cost of testing. The
mPCRmethod described is fast, simple, and transferable to a mo-
lecular diagnostic laboratory with basic equipment, and it can be
performed on crude gDNA derived directly from bacterial colo-
nies.
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